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Abstract
Background: High glucose could induce structure and function change in cardiomyocytes, PKC
plays a core effect in the onset and progression of diabetic cardiomyopathy, but its underlying
downstream signal transduction pathway is still not completely understood.
Objectives:  To study the influence of high glucose on the structure, function and signal
transduction pathway of PKC (Protein Kinase C)/NF-κB(Nuclear factor-κB)/c-fos in cultured
cardiomyocytes.
Methods: Using cultured cardiomyocytes of neonatal Sprague-Dawley rats as a model, groups
were divided into: control group (glucose: 5 mmol/L); high glucose group (glucose: 10 mmol/L, 15
mmol/L, 20 mmol/L, 25.5 mmol/L); equimolar mannital group (5 mmol/L glucose + 20.5 mmol/L
maninital); high glucose(25.5 mmol/L) add PKC inhibitor (Ro-31-8220, 50 nmol/L); high glucose
(25.5 mmol/L) add NF-κB inhibitor (BAY11-7082, 5 μmol/L). The cellular contracting frequency
and volumes were measured and the expression of PKC-α, PKC-β2, p-PKC-α, p-PKC-β2, NF-κB,
p-NF-κB, TNF-α (tumor necrosis factor-α) and c-fos were measured by western blot or RT-PCR.
Results: Cardiomyocytes cultured in high glucose level, but not iso-osmotic mannital, showed an
increased pulsatile frequency and higher cellular volumes consistent with the increased glucose
levels, and also higher expression of PKC-α, PKC-β2, p-PKC-α, p-PKC-β2, NF-κB, p-NF-κB, TNF-
α and c-fos. The addition of Ro-31-8220 and BAY11-7082 could partly reverse these changes
induced by high glucose level.
Conclusion: High glucose significantly increased the pulsatile frequency and cellular volumes of
cultured cardiomyocytes via PKC/NF-κB/c-fos pathway, which might lead to diabetic
cardiomyopathy.
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Background
Diabetes mellitus is a state of chronic hyperglycemia due
to an absolute or relative deficiency of insulin secretion
that may or may not be associated with insulin resistance.
The worldwide prevalence of diabetes was estimated to be
2.8% in 2000 and is projected to reach 4.4% by 2030[1].
Diabetic cardiomyopathy is one of the most prevalent car-
diovascular complications of diabetes mellitus that occurs
independently of coronary artery disease and hyperten-
sion[2]. Many epidemiological and clinical studies have
shown that chronic hyperglycemia is a major initiator of
diabetic microvascular and cardiovascular complications
as high glucose may regulate the growth of cardiomyo-
cytes via activates several signal transduction pathways[3].
For example, hyperglycemia could accelerate polyol path-
way flux, alter cellular redox state, increase formation of
diacylglycerol (DAG) and the subsequent activation of
protein kinase C (PKC) isoforms and augmented non-
enzymatic formation of advanced glycated end products,
which cause the extracellular matrix to change and induce
hypertrophy of cardiomyocytes, microangiopathy of
heart, fibrosis of interstitial substance, which eventually
leading to heart failure[4,5]. Among the signal pathways
listed above, the DAG-PKC signal pathway is considered
to be one of the most important intracellular transduction
pathways that functions as a core effect in the onset and
progression of diabetic cardiomyopathy.
Approximately more than 10 different isozymes make up
the PKC family, with respect to the heart, PKC-α and PKC-
β2 are the predominant Ca2+-dependent PKC isoforms[6].
A number of reports have associated PKC activation with
many cardiovascular abnormalities in cardiomyopathy, as
it affects cardiovascular function in many ways, such as
cardiac hypertrophy, dilated cardiomyopathy, ischemic
injury[7,8]. Studies have revealed that increased DAG lev-
els and PKC activity in diabetic cardiomyopathy are asso-
ciated with changes in blood flow, thickening in
basement membrane, expansion of extracellular matrix,
increasing in vascular permeability and abnormality of
angiogenesis. Also increased expression and activity of
PKC can lead to excessive cardiomyocyte apoptosis and
alteration of enzymatic activity such as Na+-K+-ATPase,
cPLA2, PI3 kinase and MAP kinase[9]. Otherwise, inhibi-
tion of PKC has been reported to prevent structure and
function abnormalities in cardiomyopathy, heart failure,
ischemic injury and so on[10]. Collectively, PKC activa-
tion is likely to be responsible for the pathology in dia-
betic cardiomyopathy, but the exact role that PKC plays in
the alteration of cardiomyocytes cultured in high glucose
levels and its underlying downstream signal transduction
pathway is still not completely understood.
NF-κB is a transcription factor that directly regulates the
expression of immediate-early genes and genes involved
in the stress and inflammatory response following a vari-
ety of physiological or pathological stimuli[11,12]. Stud-
ies have found that activation of NF-κB may function as a
causal event in the cardiac hypertrophic response of cardi-
omyopathy, as modeled in cultured cardiomyocytes and
that NF-κB inhibition could attenuate or block the hyper-
trophy of cultured cardiomyocytes[13,14]. Recent studies
have shown that oxidative stress generated by hyperglyc-
emia is one of the major mediators of cardiac hypertrophy
and dysfunction in diabetic cardiomyopathy, so NF-κB
may function as a necessary mediator of the cardiac
response in the pathogenesis of diabetic cardiomyopathy.
TNF-α is recognized as a significant contributor to myo-
cardial dysfunction. Cardiomyocytes have been identified
as a principal target of the proinflammatory actions of
TNF-α. Significantly increased TNF-α expression is found
in cardiac hypertrophy induced in stretched myocytes and
in hemodynamic-over-loaded myocardium[15]. In heart
failure, TNF-α transcription can be activated by NF-κB,
and NF-κB itself is also dominantly regulated by TNF-α, as
the increased expression of TNF-α triggers NF-κB translo-
cation to the nucleus where it activates transcription of
many inflammatory and immune response target genes.
c-fos is one of the immediate early genes and fetal contrac-
tile protein genes that regulates protein synthesis in cardi-
omyocytes. It is reported to be stimulated in ischemic
injury, heart failure and cardiomyopathy[16]. What's
more, increased expression of c-fos has also been reported
in both Ang II-induced or mechanical stress-induced car-
diomyocytes hypertrophy. PKC/c-fos pathway has been
shown to be involved in endothelin-1-induced prolifera-
tion and hypertrophy of rat cardiac myocytes[17]. In this
research, we used cultured neonatal ventricular myocytes
as a model to study the influence of high glucose levels on
the structure, function and expression of PKC, NF-κB,
TNF-α and c-fos in cardiomyocytes, and tried to study the
effect of PKC/NF-κB/c-fos signal transduction pathway in
the pathogenesis of diabetic cardiomyopathy.
Methods
1. Materials
1.1 Experimental animals
1 day old Sprague-Dawley rats (provided by experimental
animal center of Zhejiang University, Hangzhou, China),
the investigation conforms with the Guide for the Care
and Use of Laboratory Animals Published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996), and approval was granted by the university
ethics review board, all procedures and materials prepared
from animals were performed in accordance with institu-
tional policies and guidelines.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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1.2 Drug and chemicals
Trypsin and DMEM were purchased from Gibico Chemi-
cal Co. Glucose, mannital, Ro-31-8220 and BAY11-7082
were obtained from Sigma Chemical Co. The concentra-
tions of drugs used were based on previous studies. Pri-
mary antibodies included mouse anti PKC-α, rabbit anti
PKC-β2, goat anti p-PKC-α, goat anti p-PKC-β2, mouse
anti NF-κB, mouse anti p-NF-κB and rabbit anti c-fos anti-
body(Santa Cruz), Second antibodies included goat anti
mouse, goat anti rabbit, rabbit anti goat antibody (Santa
Cruz). The TNF-α primer (387 bp): 5'-GAA CAA CCC TAC
GAG CAC CT-3'; 5'-GGG TAG TTT GGC TGG GAT AA-3'.
dNTPs, Taq enzyme, M-MULV, MgCl2, RNasin were pur-
chased from Promega Co; Oligo(dT) was obtained from
Shanghai Sangon Biological Engineering Technology &
Services Co.
2. Methods
2.1 Culture of neonatal rat ventricular myocytes
1 day old Sprague-Dawley rats were sacrificed and their
hearts were dissected. The ventricle was isolated, and
digested with a buffer solution containing trypsin and col-
lagenase for 20 min at 37°C. Ventricular myocytes were
cultured described previously[18,19]. The cell superna-
tant was collected by centrifugation, after which pellet was
resuspended and collected by centrifugation again, then
resuspended with DMEM cell culture medium contain
15% fetal bovine serum. The above steps were repeated 3
to 5 times until the ventricles were completely digested.
The cell suspension was then diluted to (1–5) × l05/ml
with DMEM cell culture medium contain 15% fetal
bovine serum and penicillin-streptomycin and were
placed in 6-well cell culture plates in humidified 5% CO2,
95% air atmosphere at 37°C. In the first three days, 5-Bru
(0.1 mmol/L) was added to the culture medium to inhibit
the growth of fibroblast[20]. Twenty-four hours after
seeding, the culture medium was changed to serum-free
DMEM and the cells were divided into different groups
and cultured for another 48 h.
2.2 Groups divided
After the initial culture, cells were divided into different
glucose levels according to previously described
researches as follow: control glucose (5 mmol/L) group, a
high glucose (10 mmol/L, 15 mmol/L, 20 mmol/L, 25.5
mmol/L) group serials, equimolar mannital group (5
mmol/L glucose+20 mmol/L maninital); a high glucose
add PKC inhibitor Ro-31-8220 (50 nmol/L) group and a
high glucose add NF-κB inhibitor BAY11-7082 (5 μmol/
L) group [21-23]. After the addition of those drugs, the
cardiomyocytes in different groups were continued to be
cultured for 48 h.
2.3 Determination of cellular pulsatile frequency
Inverted microscope and dish were put into lucite cou-
veuse, which equipped with homoiothermy air convec-
tion assembly. Make sure the dishes were covered fully by
convection air at 37°C. For the study of cellular pulsatile
frequency, five fields were randomly chosen from each
group, and 20 individual cells were counted from each
field at high power (×400)ocular lens of inverted micro-
scope.
2.4 Measurement of cell size
The volume of ventricular myocytes was obtained by
measuring cellular diameter under an inverted micro-
scope. For cell size measurements, five fields were ran-
domly chosen from each group and 20 individual cells
were counted from each field.
2.5 Western blot analysis
The cells were washed twice with PBS and lysed at 4°C
with lysis buffer, equal amounts of nuclear or total protein
prepared from each lysate were resolved by SDS/PAGE
[10%(w/v) gel] and transferred on PVDF membranes.
After the membranes were washed with TBS (Tris-buffered
solution) buffer to remove the stain, the filters were
blocked with 5% nonfat milk in TBS for 1 hour at room
temperature, and then incubated with diluted primary
antibodies overnight at 4°C. After being washed three
times with TBST (Tris-buffered solution containing 0.1%
Tween 20) buffer for 10 min each, the filters were then
incubation with horseradish peroxidase-conjugated sec-
ond antibodies for 1 h, followed by washing three times
with TBST buffer for 10 min each, at last the proteins were
detected in the linear range of X-ray film by chemilumi-
nescence reagent plus (ECL).
2.6 RT-PCR analysis
The cultured cardiomyocytes were washed twice with PBS
and lysed in 1 ml of Trizol reagent for 5 min. Total RNA
was isolated with Trizol reagent according to the manufac-
turer's instruction. Total RNA was reversely transcribed
and subsequently amplified by PCR using primers listed
above. The resulting products were separated on 1.2%
agarose gel and stained with ethidium bromide. The
intensity of the bands was quantified by an image analysis
scanning system, and normalized by GAPDH as control.
2.7 Statistics
Each experiment shown was performed a minimum of
three times, all data were presented as mean ± SE, and
were analyzed by using SPSS 15.0 software. Comparisons
among groups were made by an unpaired student's t test.
A value of P < 0.05 was considered statistically significant.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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Results
3.1 Effect of different glucose levels on the pulsatile 
frequency and cellular size of cultured cardiomyocytes
After adding different treatment factors to different
groups, and culturing for an additional 48 hours, the pul-
satile frequency and cellular size of cardiomyocytes cul-
tured in different glucose levels changed consistent with
the increased glucose levels, but were unaffected by
maninital as shown in Table 1. The cellular pulsatile fre-
quency and diameters in different groups showed signifi-
cant difference between each other, which all had
statistical significance.
3.2 Effect of PKC inhibitor Ro-31-8220 and NF-κB inhibitor 
BAY11-7082 on the pulsatile frequency and cellular size of 
cardiomyocytes cultured in high glucose levels
The cardiomyocytes were divided into normal glucose (5
mmol/L), high glucose (25.5 mmol/L), high glucose add-
ing Ro-31-8220 (50 nmol/L), high glucose adding BAY11-
7082 (5 μmol/L), mannital (glucose 5 mmol/L+mannital
20.5 mmol/L), and cultured for an additional 48 hours.
Compared with normal glucose group, the cellular pulsa-
tile frequency and size of cardiomyocytes cultured in high
glucose increased significantly, but not in iso-osmotic
mannital group, after adding Ro-31-8220 and BAY11-
7082, the pulsatile frequency and size of the cells all
decreased significantly. The result was shown in Table 2.
3.3 Effect of high glucose and PKC inhibitor Ro-31-8220 on 
the expression and activity of PKC in cardiomyocytes
The cardiomyocytes were divided into normal glucose (5
mmol/L), high glucose (25.5 mmol/L), high glucose add-
ing Ro-31-8220 (50 nmol/L), mannital (glucose 5 mmol/
L+mannital 20.5 mmol/L). After culturing for an addi-
tional 48 hours, the expression and activity of PKC-α and
PKC-β2 were examined by western blot. Cardiomyocytes
cultured in high glucose levels showed higher expression
of PKC-α, PKC-β2 and increased activity of PKC-α, PKC-
β2 at the same time, as reflected by higher expression of p-
PKC-α, p-PKC-β2 compared with control group. After
adding PKC inhibitor Ro-31-8220, the expression and
activity of PKC-α, PKC-β2 decreased compared with the
cardiomyocytes cultured in high glucose levels as shown
in figure 1 and figure 2. Treatment with mannital, used as
an osmotic control, had no significant effect on the
expression of PKC-α and PKC-β2 in cardiomyocytes.
3.4 Effect of high glucose and PKC inhibitor Ro-31-8220, 
NF-κB inhibitor BAY11-7082 on the expression and activity 
of NF-κB in cardiomyocytes
The cardiomyocytes were divided into normal glucose (5
mmol/L), high glucose (25.5 mmol/L), high glucose add-
ing Ro-31-8220 (50 nmol/L), high glucose adding BAY11-
7082 (5 μmol/L), mannital (glucose 5 mmol/L+mannital
20.5 mmol/L). After culturing for an additional 48 hours,
the expression of both total and nuclear NF-κB were
examined by western blot. Total and nuclear expression of
NF-κB, p-NF-κB all increased in cardiomyocytes cultured
in high glucose levels compared with control group. After
adding PKC inhibitor Ro-31-8220 and NF-κB inhibitor
BAY11-7082, the whole or nuclear expression and activity
of NF-κB decreased as shown in figure 3 and figure 4.
Treatment with mannital, used as an osmotic control, had
no significant effect on the expression of NF-κB in cardio-
myocytes.
3.5 Effect of high glucose and PKC inhibitor Ro-31-8220, 
NF-κB inhibitor BAY11-7082 on the expression of TNF-α in 
cardiomyocytes
The cardiomyocytes were divided into normal glucose (5
mmol/L), high glucose (25.5 mmol/L), high glucose add-
ing Ro-31-8220 (50 nmol/L), high glucose adding BAY11-
Table 1: Effect of high glucose on pulsatile frequency and cellular size of cultured cardiomyocytes
diameter(μm) pulsatile frequency(bpm/min)
Glucose (5 mmol/L) 18.76 ± 0.88 57.86 ± 2.103
Glucose (10 mmol/L) 19.98 ± 0.81* 59.08 ± 1.947*
Glucose (15 mmol/L) 20.71 ± 0.80*# 61.16 ± 2.121*#
Glucose (20 mmol/L) 21.33 ± 0.78* Δ 63.11 ± 2.269* Δ
Glucose (25.5 mmol/L) 25.33 ± 1.37* δ 70.43 ± 3.896* δ
iso-osmotic mannital 19.62 ± 1.43 57.85 ± 2.572
The pulsatile frequency and cellular size of cardiomyocytes cultured in different glucose levels increased consistent with the increased glucose levels 
as shown table 1. Treatment with mannital, used as an osmotic control, had no significant effect on the pulsatile frequency and cellular size of 
cardiomyocytes. The results were expressed as means ± SE (n = 100). * P < 0.05 vs control 5 mmol/L glucose group, #P < 0.05 vs 10 mmol/L 
glucose group, ΔP < 0.05 vs 15 mmol/L glucose group, δP < 0.05 vs 20 mmol/L glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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7082 (5 μmol/L), mannital (glucose 5 mmol/L+mannital
20.5 mmol/L). After culturing for an additional 48 hours,
the expression of TNF-α was examined by RT-PCR. Cardi-
omyocytes cultured in high glucose levels showed higher
expression of TNF-α compared with control group. After
adding PKC inhibitor Ro-31-8220 and NF-κB inhibitor
BAY11-7082, the expression of TNF-α decreased as shown
in figure 5. Treatment with mannital, used as an osmotic
control, had no significant effect on the expression of
TNF-α in cardiomyocytes.
3.6 Effect of high glucose and PKC inhibitor Ro-31-8220, 
NF-κB inhibitor BAY11-7082 on the expression of c-fos in 
cardiomyocytes
The cardiomyocytes were divided into normal glucose (5
mmol/L), high glucose (25.5 mmol/L), high glucose add-
ing Ro-31-8220 (50 nmol/L), high glucose adding BAY11-
7082 (5 μmol/L), mannital (glucose 5 mmol/L+mannital
20.5 mmol/L). After culturing for an additional 48 hours,
the expression of c-fos was examined by western blot. Car-
diomyocytes cultured in high glucose levels showed
higher expression of c-fos compared with control group.
After adding PKC inhibitor Ro-31-8220 and NF-κB inhib-
itor BAY11-7082, the expression of c-fos decreased as
shown in figure 6. Treatment with mannital, used as an
osmotic control, had no significant effect on the expres-
sion of c-fos in cardiomyocytes.
Discussion
Diabetic cardiomyopathy is one of the most prevalent car-
diovascular complications of diabetes mellitus, occurring
independently of coronary artery disease and hyperten-
sion[2]. Its typically pathological changes include hyper-
trophy of cardiomyocytes, microangiopathy of heart and
fibrosis of interstitial substance[24]. Cardiomyopathy in
diabetic patients is characterized by early diastolic dys-
function, followed by late systolic dysfunction[25-27].
However, the mechanism underlying the development of
structure and function impairment in cardiomyopathy
remains unknown, in particular, the intracellular signal
transduction pathway that leads to the pathological
change of cardiomycyte hypertrophy is still unclear.
Our previous studies have shown that Sprague-Dawley
rats with diabetic cardiomyopathy induced by alloxanm
revealed a higher heart rate compared with control
groups, and showed hypertrophy of cardiomyocytes,
microangiopathy of heart, fibrosis of interstitial substance
and subcellular remodeling in myocardium at the end 4,
6 weeks[28]. When examined by electron microscopy, it
was characterized by damaged myofibrils and mitochon-
dria, dilated and swollen sarcoplasmic reticulum[29].
There have been studies indicated that high glucose levels
could increase the pulsatile frequency of cardiomyocytes
as hyperglycemia regulates the opening of voltage-
dependent channels existing in the cytoplasmic mem-
brane due to activation of tyrosine kinase[30]. Accelerated
pulsatile frequency could increase energy expenditure,
aggravate the impairment of cardiomyocytes induced by
high glucose levels, leading to energy insufficiency and a
series of negative manifestations. In this study, we discov-
ered that the cardiomyocytes cultured in high glucose lev-
els showed increased pulsatile frequency and obvious
hypertrophy compared with cells cultured in normal glu-
cose levels, which conforms to our previous studies.
Protein kinase C has received increasing attention in the
pathogenesis of cardiomyopathy as it has been shown to
function as a target protein for second messengers. Over-
expression of PKC-α and PKC-β2 were discovered in the
early stage of pathological development of diabetic cardi-
omyopathy because sustained hyperglycemia in diabetes
mellitus could activate DAG-PKC signal transduction
pathway, leading to increased expression of PKC in cardi-
omyocytes and translocation of PKC from cytoplasm to
cytomembrane[31-33]. The downstream signal transduc-
Table 2: Effect of Ro-31-8220 and BAY11-7082 on pulsatile frequency and cellular size of cultured cardiomyocytes
diameter(μm) pulsatile frequency(bpm/min)
Normal Glucose (5 mmol/L) 18.76 ± 0.88 57.86 ± 2.103
High Glucose (25.5 mmol/L) 25.33 ± 1.37* 70.43 ± 3.896*
High Glucose +Ro-31-8220 21.41 ± 0.80# 64.73 ± 3.336#
High Glucose + BAY11-7082 20.94 ± 0.78# 62.55 ± 2.341#
iso-osmotic mannital 19.62 ± 1.43 57.85 ± 2.572
Compared with normal glucose(5 mmol/L) group, the cellular pulsatile frequency and size of cardiomyocytes cultured in high glucose(25.5 mmol/L) 
increased significantly, but not in iso-osmotic mannital group, after adding Ro-31-8220 and BAY11-7082, the pulsatile frequency and size of the cells 
all decreased significantly. The results were expressed as means ± SE (n = 100). * P < 0.05 vs control group(glucose:5 mmol/L), #P < 0.05 vs high 
glucose group (glucose: 25.5 mmol/L).Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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Effect of high glucose levels and PKC inhibitor Ro-31-8220 on PKC-α expression in cultured cardiomyocytes Figure 1
Effect of high glucose levels and PKC inhibitor Ro-31-8220 on PKC-α expression in cultured cardiomyocytes. 
Cardiomyocytes cultured in high glucose levels showed higher expression and activity of PKC-α compared with control group. 
After adding PKC inhibitor Ro-31-8220 (50 nmol/L) to the cardiomyocytes cultured in high glucose levels, the expression and 
activity of PKC-α decreased. Treatment with mannital, used as an osmotic control, had no significant effect on the expression 
of PKC-α in cardiomyocytes. The results were shown in figure1 expressed as means ± SE (n = 4 or 5). * P < 0.05 vs control 
group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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Effect of high glucose levels and PKC inhibitor Ro-31-8220 on PKC-β2 expression in cultured cardiomyocytes Figure 2
Effect of high glucose levels and PKC inhibitor Ro-31-8220 on PKC-β2 expression in cultured cardiomyocytes. 
Cardiomyocytes cultured in high glucose levels showed higher expression and activity of PKC-β2 compared with control 
group. After adding PKC inhibitor Ro-31-8220 (50 nmol/L) to the cardiomyocytes cultured in high glucose levels, the expres-
sion and activity of PKC-β2 decreased. Treatment with mannital, used as an osmotic control, had no significant effect on the 
expression of PKC-β2 in cardiomyocytes. The results were shown in figure 2 expressed as means ± SE (n = 4 or 5). * P < 0.05 
vs control group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on total cellular NF-κB expression in cardi- omyocytes Figure 3
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on total cellular NF-κB 
expression in cardiomyocytes. Cardiomyocytes cultured in high glucose levels showed higher expression and increased 
activity of NF-κB compared with control group. After adding PKC inhibitor Ro-31-8220(50 nmol/L) and NF-κB inhibitor 
BAY11-7082(5 μmol/L), the expression and activity of NF-κB decreased as shown in figure 3. Treatment with mannital, used as 
an osmotic control, had no significant effect on the expression of NF-κB in cardiomyocytes. The results were expressed as 
means ± SE (n = 4 or 5). * P < 0.05 vs control group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on nuclear NF-κB expression in cardiomy- ocytes Figure 4
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on nuclear NF-κB expres-
sion in cardiomyocytes. Cardiomyocytes cultured in high glucose levels showed higher nuclear protein expression and 
activity of NF-κB compared with control group. After adding PKC inhibitor Ro-31-8220(50 nmol/L) and NF-κB inhibitor 
BAY11-7082(5 μmol/L) the expression and activity of nuclear NF-κB decreased as shown in figure 4. Treatment with mannital, 
used as an osmotic control, had no significant effect on the nuclear expression of NF-κB in cardiomyocytes. The results were 
expressed as means ± SE (n = 4 or 5). * P < 0.05 vs control group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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tion pathway, however, is still unclear. In our study, we
investigated whether PKC was involved in the pathogene-
sis of diabetic cardiomyopathy, with particular focused on
the role PKC plays in the onset of cardiomyocyte hypertro-
phy. In our research we found that the cardiomyocytes
cultured in high glucose levels showed increased expres-
sion and activity of PKC-α, PKCβ2, as reflected by the
higher protein expression of PKC-α, PKC-β2, p-PKC-α, p-
PKC-β2 when examined by western blot, which was in
agreement with the cellular defects induced in the cardio-
myocytes by hyperglycemia. It is known that activation of
PKC in cardiomyocyte could promote gene expression via
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on TNF-α expression in cardiomyocytes Figure 5
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on TNF-α expression in car-
diomyocytes. Cardiomyocytes cultured in high glucose levels showed higher expression of TNF-α compared with control 
group. After adding PKC inhibitor Ro-31-8220 (50 nmol/L) and NF-κB inhibitor BAY11-7082 (5 μmol/L), the expression of 
TNF-α decreased compared with the cardiomyocytes cultured in high glucose levels as shown in figure 5. Treatment with man-
nital, used as an osmotic control, had no significant effect on the expression of TNF-α in cardiomyocytes. The results were 
expressed as means ± SE (n = 4 or 5). * P < 0.05 vs control group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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many signal transduction pathways, such as MAPK
(mitogen-activated protein kinase, MAPK), which can reg-
ulate the growth of cardiomyocytes. Other studies that
done on ischemic and heart failure animal models have
also shown that over-expression and activity of PKC could
induce the expression of proto-oncogene such as c-fos, c-
jun, leading to increased AP-1 (activator protein), with
AP-1 potentially stimulate the transcription of type IV col-
lagen, fibronectin, TGF-β and so on. In addition, many
studies focused on heart failure have also discovered over-
transcription of type IV collagen, fibronectin, TGF-β could
induce impaired contractility of cardiomyocytes,
increased accumulation of extracellular matrix and also
hypertrophy of cardiomyocytes, microangiopathy of heart
and fibrosis of interstitial substance, which at last leads to
heart failure.
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on c-fos expression in cardiomyocytes Figure 6
Effect of high glucose and PKC inhibitor Ro-31-8220, NF-κB inhibitor BAY11-7082 on c-fos expression in cardi-
omyocytes. Cardiomyocytes cultured in high glucose levels showed higher expression of c-fos compared with control group. 
After adding PKC inhibitor Ro-31-8220(50 nmol/L) and NF-κB inhibitor BAY11-7082(5 μmol/L) to the cardiomyocytes cul-
tured in high glucose levels, the expression of c-fos decreased as shown in figure 6. Treatment with mannital, used as an 
osmotic control, had no significant effect on the expression of c-fos in cardiomyocytes. The results were expressed as means ± 
SE (n = 4 or 5). * P < 0.05 vs control group, #P < 0.05 vs high glucose group.Cardiovascular Diabetology 2009, 8:8 http://www.cardiab.com/content/8/1/8
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To further investigate and explain the mechanism of PKC
on the high glucose induced cardiomyocyte impairment,
we examined the expression of NF-κB, TNF-α and c-fos at
the same time. We found that cardiomyocytes cultured in
high glucose levels showed increased expression of NF-κB,
TNF-α and c-fos compared with those cultured in the nor-
mal control glucose levels, and there was a significant dif-
ference existing between the two groups. NF-κB is a
transcription factor that can directly regulate the expres-
sion of immediate-early genes and other genes involved in
the stress response following a variety of physiological or
pathological stimuli, and NF-κB inhibition could attenu-
ate or block the hypertrophic response of cultured cardio-
myocytes[34]. Recent studies have shown that oxidative
stress generated by hyperglycemia is one of the major
mediators of diabetic cardiomyopathy, and activation of
NF-κB is a possible mechanism for oxidative stress-
induced cardiovascular complications in diabetes. On the
assumption that NF-κB activated by PKC may function as
a core effect in the cardiac hypertrophic response of dia-
betic cardiomyopathy, as modeled in cultured cardiomy-
ocytes, we used PKCα/β2 inhibitor (Ro-31-8220) and NF-
κB inhibitor (BAY11-7082) to study the signal transduc-
tion pathway of PKC and its downstream effect on NF-κB.
We discovered that after using the selective PKCα/β2
inhibitor Ro-31-8220, the hypertrophy of cardiomyocytes
induced by high glucose concentration was obviously
reversed, with the depressed expression of both PKC-α,
PKC-β2 as well as NF-κB, TNF-α and c-fos. Similarly, after
using the NF-κB inhibitor BAY11-7082, both the cardiac
hypertrophy and the increased expression of NF-κB, TNF-
α, c-fos were reversed remarkably. For this phenomenon,
we supposed that hyperglycemia could result in a higher
content of intracellular DAG in the cardiomyocytes, lead-
ing to increased expression and activity of PKC-α, PKC-β2,
then inducing over-expression of NF-κB via PKC-IKK-NF-
κB signal transduction pathway[35]. It is known that after
entering cellular nucleus, NF-κB could increase the tran-
scription of a number of inflammatory cytokines, includ-
ing TNF-α, which is one of the relevant mediators of
cardiomyopathy disease states[36-39]. For example, TNF-
α was proved to modulate heart failure by provoking
hypertrophic growth in cardiac myocytes, and a recent
study in neonatal cardiac myocytes showed that TNF was
sufficient to trigger cardiac myocyte hypertrophy. So TNF-
α was considered as parameters of hypertrophy that could
be induced by angiotension II, endothelin-1, phenyle-
phrine, myotrophin and so on, but it could be obviously
inhibited through over-expression of degradation resist-
ant mutant of IêBα, which support the hypothesis that
increased NF-κB expression and consequently activation
of TNF-α is involved in the cardiomyocyte hypertrophic
response induced by high glucose levels[40,41]. Studies
have demonstrated that the increased expression of TNF-
α could further lead to the expression of proto-oncogene,
such as c-fos, which would result in an accelerated rate of
general protein synthesis, as well as an increase in LV mass
caused by increased cell size and protein content of cardi-
omyocytes. Increased expression of c-fos was viewed as an
adaptive response for maintaining cardiac output after
stimulation of with TNF or AngII, as in isolated adult car-
diac myocytes or heart failure, ischemic injury and stress-
induced hypertrophy models. Those pathological changes
ultimately result in remodeling of the cardiac muscle,
leading to development of diabetic cardiomyopathy.
In conclusion, our study indicated for the first time that
high glucose levels can significantly influence the struc-
ture and function of cultured cardiomyocytes, causing car-
diac hypertrophy that may occur via PKC/NF-κB/c-fos
pathway, which leads to diabetic cardiomyopathy.
Conclusion
Our study indicated for the first time that high glucose lev-
els can significantly influence the structure and function
of cultured cardiomyocytes, causing cardiac hypertrophy
via PKC signal transduction pathway, which may lead to
diabetic cardiomyopathy.
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